Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

chris.buyse@thrombogenics.com .

Citigate Dewe Rogerson:

Amber Bielecka/ David Dible/ Nina Enegren, Tel: +44(0)207-638-95-71,

amber.bielecka@citigatedr.co.uk

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent in stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reaso
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  An entire month ... of inherited neuropathies – Charcot-Marie-Tooth disease (CMT) – a ... legs, causing extreme muscle atrophy, weakness, and foot and ... US and millions worldwide. CMT is a progressive disease, ... their legs, requiring mobility devices such as leg braces, ...
(Date:9/19/2014)... Sept. 19, 2014 Pfenex Inc. (NYSE MKT: ... of high-value and difficult to manufacture proteins including biosimilar ... the 21 st Annual NewsMakers in the Biotech ... Bertrand Liang , chief executive officer of Pfenex, ... and business strategy on Friday, September 26, 2014 at ...
(Date:9/19/2014)... September 19, 2014 Cereal grain ... industries will gather October 5–8, 2014, for the ... Island Convention Center in Providence, Rhode Island. The ... work of food scientists, chemists, microbiologists, nutritionists, and ... food production management. To date, 1,000 attendees have ...
(Date:9/19/2014)... 2014 The new , Healthcare and ... available today on PharmaBoardroom.com for free download ... rocked the Spanish economy in 2009, and the austerity measures ... remained pragmatic in times of trouble. "Despite the ... biggest European market, and the general conditions to invest are ...
Breaking Biology Technology:September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Pfenex to Present at Upcoming Industry Conference on September 26 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3
... , , SAN DIEGO , ... BMR ) today announced the signing of an amendment to its ... 301 Binney Street laboratory research facility in Cambridge, Massachusetts . ... laboratory and office space contiguous to its existing premises located in ...
... , , ... Reportlinker.com announces that a new market research ... The Future of Nutrigenomics: New opportunities in ... http://www.reportlinker.com/p0177850/The-Future-of-Nutrigenomics-New-opportunities-in-personalized-nutrition-and-food-pharma-collaboration.html , Nutrigenomics explores how nutrients ...
... , CRANBURY, N.J. , Feb. 16 ... for its second quarter ended December 31, 2009 .  Palatin reported net ... diluted share, for the quarter ended December 31, 2009 , compared to ... basic and diluted share, for the same period in 2008.  Total revenues in ...
Cached Biology Technology:BioMed Realty Trust Expands Lease With Ironwood Pharmaceuticals for 50,000 Square Feet in Cambridge, Massachusetts 2BioMed Realty Trust Expands Lease With Ironwood Pharmaceuticals for 50,000 Square Feet in Cambridge, Massachusetts 3BioMed Realty Trust Expands Lease With Ironwood Pharmaceuticals for 50,000 Square Feet in Cambridge, Massachusetts 4Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 2Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 3Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 4Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 5Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 6Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 2Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 3Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 4Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 5Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 6Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 7
(Date:9/17/2014)... atmospheric scientists were instrumental in the creation of the ... to classify the fire threat potential of the powerful, ... spark into an inferno. The index was introduced Sept. ... UCLA and San Diego Gas and Electric. , The ... "extreme" that will be used to help fire agencies ...
(Date:9/17/2014)... engineering professor and his doctoral student have designed a ... water collected from fog and dew., The device could ... deserts around the globe., Cheng Luo, professor in the ... candidate in the same College of Engineering department, published ... of ACS, (American Chemical Society) Applied Materials ...
(Date:9/17/2014)... 17, 2014) A rare genetic disorder known as Jacobsen ... recent joint investigation by researchers at San Diego State ... addition to suggesting better treatment options for people with ... the genetic underpinnings of autism., Jacobsen syndrome affects approximately ... of Health. It occurs in a person when there ...
Breaking Biology News(10 mins):UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2Shorebird's beak inspires UT Arlington research on water collection 2A link between Jacobsen syndrome and autism 2
... cells in the eye receptive to light is missing in ... animals like birds, fish and amphibians have two versions of ... The findings ?published in the Public Library of Science journal ... may be impoverished compared to other vertebrates and fits with ...
... Waiting a day or more to get lab results back ... a past. Using nanotechnology, a team of University of Georgia ... as diverse as influenza, HIV and RSV in 60 seconds ... ?which is detailed in the November issue of the journal ...
... 12, 2006 -- A new study in Journal of the ... over smaller shrimp of the same gender when competing for ... though adult males of the species are typically much smaller ... size and gender are important factors in acquiring food," says ...
Cached Biology News:Does missing gene point to nocturnal existence for early mammals? 2Silver bullet: UGA researchers use laser, nanotechnology to rapidly detect viruses 2Silver bullet: UGA researchers use laser, nanotechnology to rapidly detect viruses 3
... NightOWL is a dedicated imaging system ... size. Equipped with a very sensitive camera ... or plants in tumor research, infectious disease ... Western blots. NightOWL is the only imager ...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse polyclonal antibody raised against a partial recombinant AGTRAP. NCBI Entrez Gene ID = 57085...
Mouse polyclonal antibody raised against a partial recombinant NCLN. NCBI Entrez Gene ID = 56926...
Biology Products: